|
1. |
Recombinant T-Cell Receptors: An Immunologic Link to Cancer Therapy |
|
Journal of Immunotherapy,
Volume 23,
Issue 4,
2000,
Page 393-400
Anna Calogero,
Lou F de Leij,
Nanno Mulder,
Geke Hospers,
Preview
|
PDF (213KB)
|
|
摘要:
Cytotoxic T cells can specifically kill target cells that express antigens recognized by the T-cell receptor. These are membrane-bound proteins that are not ubiquitous and thus are difficult to purify and study at the protein level. The advent of recombinant DNA technology has facilitated these objectives, thereby enabling researchers to gain valuable information about major T-cell receptor characteristics. Genetic manipulation of T-cell receptors has also been used to exploit specificity of killing by cytotoxic T lymphocytes, which represents an attractive feature for therapeutic purposes. The objective of this review was to provide an overview of the major strategies adopted to genetically manipulate T-cell receptors.
ISSN:1524-9557
出版商:OVID
年代:2000
数据来源: OVID
|
2. |
Long-Term Survival of Anti-Tumor Lymphocytes Generated by Vaccination of Patients With Melanoma With a Peptide Vaccine |
|
Journal of Immunotherapy,
Volume 23,
Issue 4,
2000,
Page 401-404
John Stewart,
Steven Rosenberg,
Preview
|
PDF (97KB)
|
|
摘要:
Immunization with the modified gp100 melanoma peptide gp100:109-217 (210M) in Incomplete Freund's Adjuvant (IFA) results in the generation of anti-peptide and antitumor lymphocytes in the patients' circulation. In this study, the authors have evaluated the persistence of these immune cells. Reactivity against the native peptide persisted for 138 to 403 days after immunization. Reactivity also persisted in three of five patients that received external beam radiotherapy and in both patients who received systemic chemotherapy after the completion of peptide immunization. Thus, immune lymphocytes with anti gp100:209-217 peptide activity appear to persist for prolonged periods after vaccination with modified peptide in IFA.
ISSN:1524-9557
出版商:OVID
年代:2000
数据来源: OVID
|
3. |
Amino Acid Substitutions in the Melanoma Antigen Recognized by T Cell 1 Peptide Modulate Cytokine Responses in Melanoma-Specific T Cells |
|
Journal of Immunotherapy,
Volume 23,
Issue 4,
2000,
Page 405-411
Mai-Britt Nielsen,
Alexei Kirkin,
Douglas Loftus,
Mogens Nissen,
Licia Rivoltini,
Jesper Zeuthen,
Carsten Geisler,
Niels Odum,
Preview
|
PDF (2351KB)
|
|
摘要:
Single amino acid substitutions in melanoma-associated peptides dramatically enhance T-cell cytotoxicity against target cells presenting the modified peptides (often referred to as heteroclitic peptides). The authors tried to determine whether peptide modifications influence other aspects of T-cell immunity toward malignant melanoma. A heteroclitic peptide, E26F, with an E to F substitution in melanoma antigen recognized by T cell 1 (MART-1)26-35, triggers an enhanced tyrosine phosphorylation response when compared with the native-and other-modified MART-1 peptides. Similarly, the E26F peptide enhances the production of mRNA for interleukin (IL)-5, IL-10, IL-13, IL-15, and interferon-&ggr; and significantly enhances release of IL-13 and IL-10 from anti–MART-1 cytotoxic T cells. Another heteroclitic peptide, 1L, with an A to L substitution in MART-127-35, also enhances the tyrosine phosphorylation response in anti–MART-1 cytotoxic CD8+T cells. Yet, 1L does not enhance the production of T helper cell type 2–like cytokines (IL-10 and IL-13). Together these data show that minor amino acid modifications of immunodominant melanoma peptides profoundly influence the cytokine response in melanoma-specific T cells.
ISSN:1524-9557
出版商:OVID
年代:2000
数据来源: OVID
|
4. |
Induction of Cytotoxic T Lymphocytes With Dendritic Cells Transfected With Human Papillomavirus E6 and E7 RNA: Implications for Cervical Cancer Immunotherapy |
|
Journal of Immunotherapy,
Volume 23,
Issue 4,
2000,
Page 412-418
Courtney Thornburg,
David Boczkowski,
Eli Gilboa,
Smita Nair,
Preview
|
PDF (1411KB)
|
|
摘要:
Human papillomavirus (HPV) infection is associated with cervical cancer. The high-risk HPV E6 and E7 oncoproteins are constitutively expressed in most cervical carcinoma cells, and are, therefore, attractive antigens for cytotoxic T-lymphocyte (CTL)–mediated immunotherapy. The objective of this study was to evaluate the use of dendritic cells (DCs) transfected with RNA encoding the E6 and E7 protein for cervical cancer immunotherapy. The authors have shown that DCs transfected with RNA-encoding antigen stimulate potent antigen-specific CTL responses in vitro and in vivo. In this study, they tried to determine whether DCs transfected with E6 and E7 RNA stimulate primary, antigen-specific CTL responses in vitro. The results show that DCs pulsed with E6 or E7 RNA stimulate antigen-specific CTL responses that recognize and lyse DCs transfected with E6 and E7 RNA and human cervical carcinoma cells expressing the E6 and E7 products, and the lysis was comparable to that achieved with E6 and E7 peptide-pulsed DCs. Dendritic cells cotransfected with both E6 and E7 RNA stimulate CTLs that are more effective at lysing human cervical cancer cells. This study provides a rationale for the development of cervical carcinoma immunotherapy using DCs transfected with HPV E6 and E7 RNA.
ISSN:1524-9557
出版商:OVID
年代:2000
数据来源: OVID
|
5. |
Quantitation of T-Cell Receptor Frequencies by Competitive Polymerase Chain Reaction: Dynamics of T-Cell Clonotype Frequencies in an Expanding Tumor-Infiltrating Lymphocyte Culture |
|
Journal of Immunotherapy,
Volume 23,
Issue 4,
2000,
Page 419-429
Mark McKee,
Timothy Clay,
Rochelle Diamond,
Steven Rosenberg,
Michael Nishimura,
Preview
|
PDF (1092KB)
|
|
摘要:
The use of T-cell receptor (TCR) genes as markers for antigen-reactive T cells is dependent on the ability of the TCR genes to rapidly identify antigen-reactive T-cell clonotypes in patient samples. We recently reported a competitive reverse-transcriptase polymerase chain reaction (cRT-PCR) method that can measure the frequency of individual TCRBV subfamilies and clonotypes in mixed lymphocyte populations more accurately than other semiquantitative PCR assays. However, it is impractical to measure changes in the absolute frequency of each TCRBV subfamily to identify those T cells with increasing frequency after antigen stimulation in vivo or in vitro. Therefore, we have modified our cRT-PCR method to more rapidly identify expanding T-cell populations by combining all of the TCRBV subfamily-specific competitors into a single sample to determine the relative abundance of each TCRBV subfamily. Using an expanding TIL 620 culture, we identified four TCRBV (BV2, BV12, BV17, and BV23) subfamilies that expanded over a 23-day period. These subfamilies accounted for 23% of the T cells in the day 35 culture and increased to 57%, 92%, and 80% of the days 44, 51, and 58 cultures respectively. Analysis of DNA sequences demonstrated that the observed expansion was caused primarily by a single clonotype within each subfamily. T cells expressing BV17 and BV23 recognized gp100 and MART-1 respectively. Therefore, this cRT-PCR method can detect expanding T-cell populations based solely on their TCRBV subfamily expression. Furthermore, T-cell expansion in a mixed TIL population was a good predictor of antigen reactivity.
ISSN:1524-9557
出版商:OVID
年代:2000
数据来源: OVID
|
6. |
Enhanced Therapeutic Potential of Adoptive Immunotherapy by In Vitro CD28/4-1BB Costimulation of Tumor-Reactive T Cells Against a Poorly Immunogenic, Major Histocompatibility Complex Class I-Negative A9P Melanoma |
|
Journal of Immunotherapy,
Volume 23,
Issue 4,
2000,
Page 430-437
Scott Strome,
Beth Martin,
Dallas Flies,
Koji Tamada,
Andrei Chapoval,
Daniel Sargent,
Suyu Shu,
Lieping Chen,
Preview
|
PDF (170KB)
|
|
摘要:
Costimulation plays a critical role in T-cell activation and amplification of anti-tumor immunity. Although CD28 engagement triggers an early activation signal, activation-induced 4-1BB molecule on T cells transmits a crucial signal for further expansion and maturation of effector cells. In this report, the authors show that costimulation through CD28 and 4-1BB pathways synergistically enhances the therapeutic efficacy of T cells from tumor-draining lymph nodes. Intravenous adoptive transfer of costimulated T cells into mice bearing disseminated micrometastasis of a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma results in a 60% cure rate. Autopsy of mice that died after unsuccessful treatment revealed tumor growth in the liver, spleen, and skin with minimal or no evidence of pulmonary disease. In contrast, mice that received no treatment or noncostimulated T cells had massive pulmonary tumors, suggesting that adoptively transferred T cells are less effective against growth of extrapulmonary tumors. These results show that costimulation of tumor-draining lymph node T cells through CD28 and 4-1BB increases their potential for cancer immunotherapy and suggests that improper trafficking of tumor-reactive T cells to extrapulmonary sites must be improved to enhance clinical efficacy.
ISSN:1524-9557
出版商:OVID
年代:2000
数据来源: OVID
|
7. |
Intracranial Paracrine Interleukin-2 Therapy Stimulates Prolonged Antitumor Immunity That Extends Outside the Central Nervous System |
|
Journal of Immunotherapy,
Volume 23,
Issue 4,
2000,
Page 438-448
Matthew Ewend,
Reid Thompson,
Richard Anderson,
Allen Sills,
Kevin Staveley-O'Carroll,
Betty Tyler,
Justin Hanes,
Daniel Brat,
Matthew Thomas,
Elizabeth Jaffee,
Drew Pardoll,
Henry Brem,
Preview
|
PDF (321KB)
|
|
摘要:
To explore the potential efficacy of local cytokine delivery against tumors in the central nervous system (CNS), C57BL6 mice were simultaneously given intracranial injections of tumor challenge and of irradiated B16F10 melanoma cells transduced to secrete interleukin-2 (IL-2). Intracranial IL-2 therapy generated antitumor responses capable of extending the survival of animals that received simultaneous intracranial tumor challenge either locally or at distant sites in the brain. Nontransduced melanoma cells had little effect. Animals that survived intracranial IL-2 therapy and tumor challenge showed prolonged survival compared with controls when challenged with a second tumor dose 70 days after initial treatment. In addition, animals that rejected intracranial tumors were also protected from tumor growth upon rechallenge at sites outside the CNS (i.e., subcutaneous tumor challenge). Conversely, identical or 10-fold larger doses of IL-2–transduced cells administered by subcutaneous injection failed to generate protection against intracranial tumor challenges. Elimination of T-cell and natural killer (NK) subsets using gene knockout mice and antibody-depletion techniques demonstrated that NK cells were most important for the initial antitumor response, whereas CD4+T-cells were not necessary. These studies demonstrate that local IL-2 therapy in the brain not only generates an immediate local antitumor immune response, but also establishes long-term immunologic memory capable of eliminating subsequent tumor challenges within and outside of the CNS. Furthermore, the antitumor response to paracrine IL-2 in the brain differed significantly from that in the flank, suggesting that the intrinsic CNS cells involved in initiating immunity within the brain have different cytokine requirements from their peripheral counterparts.
ISSN:1524-9557
出版商:OVID
年代:2000
数据来源: OVID
|
8. |
Tumor Necrosis Factor-&agr; Augments Tumor Effects in Isolated Hepatic Perfusion With Melphalan in a Rat Sarcoma Model |
|
Journal of Immunotherapy,
Volume 23,
Issue 4,
2000,
Page 449-455
Marc van Ijken,
Boudewijn van Etten,
Johannes de Wilt,
Sandra van Tiel,
Timo ten Hagen,
Alexander Eggermont,
Preview
|
PDF (94KB)
|
|
摘要:
Isolated hepatic perfusion (IHP) is an attractive approach to treating nonresectable liver tumors, because the effects of systemic chemotherapy are poor and its application is hampered by severe general toxicity. In clinical and experimental settings, the efficacy of isolated limb perfusion (ILP) with tumor necrosis factor-&agr; (TNF&agr;) in combination with melphalan to treat melanoma in transit and soft-tissue sarcoma has been well established. In an ILP model in rats, the authors previously observed synergistic anti-tumor effects of TNF and melphalan on BN 175 soft-tissue sarcoma extremity tumors. The aim of the current study was to determine whether similar synergy in anti-tumor effects could be achieved by treating experimental BN 175 soft-tissue sarcoma liver tumors by IHP using these agents. The authors found that IHP with TNF and melphalan resulted in a dramatic increase in regional concentrations of perfused agents with virtually no concomitant systemic leakage. Isolated hepatic perfusion with only carrier solution resulted in a significantly diminished growth rate of BN 175 liver tumors compared with the growth rate of tumors in nonperfused rats. Perfusion with melphalan alone resulted in minimal anti-tumor effects. Perfusion with only TNF had a slight growth-stimulatory effect on the BN 175 liver tumors, but no negative effects on tumor growth were observed. When TNF was added to melphalan, a dramatic anti-tumor effect was observed. Thus, as in the rat ILP setting, the anti-tumor effect is augmented when TNF is added to IHP with melphalan to treat BN 175 soft-tissue sarcoma tumor-bearing rats. Strikingly, the tumor response was potentiated at relatively low concentrations of TNF compared with concentrations that elicited synergy with melphalan in ILP.
ISSN:1524-9557
出版商:OVID
年代:2000
数据来源: OVID
|
9. |
Induction of Tumor-Specific Immunity in Mice by Immunization With Reconstituted Tumor Membrane Liposomes Containing Recombinant B7-2 (CD86) |
|
Journal of Immunotherapy,
Volume 23,
Issue 4,
2000,
Page 456-463
Larry Westerman,
Solomon Sund,
Periasamy Selvaraj,
Peter Jensen,
Preview
|
PDF (330KB)
|
|
摘要:
There has been considerable interest in developing experimental vaccines using genetically modified tumor cells expressing cytokines or costimulatory molecules to enhance immunogenicity. The authors investigated an alternative approach of using protein transfer rather than gene transfer to introduce costimulatory molecules rapidly into tumor membranes. Immunization with a single dose of reconstituted tumor membrane liposomes containing purified recombinant B7-2 (CD86) induced tumor rejection in mice challenged with syngeneic tumors, including the poorly immunogenic AG104A fibrosarcoma. These findings support the possibility that cell-free vaccines composed of reconstituted tumor membrane liposomes containing additional immunostimulatory proteins may offer a practical and safe alternative to genetically modified tumor cells for treating human cancer.
ISSN:1524-9557
出版商:OVID
年代:2000
数据来源: OVID
|
10. |
Increase of the Immunostimulatory Effect of Dendritic Cells by Pulsing With CA 19-9 Protein |
|
Journal of Immunotherapy,
Volume 23,
Issue 4,
2000,
Page 464-472
Angela Märten,
Björn Schöttker,
Carsten Ziske,
Silvia Weineck,
Peter Buttgereit,
Dieter Huhn,
Tilman Sauerbruch,
Ingo Schmidt-Wolf,
Preview
|
PDF (16853KB)
|
|
摘要:
Previously, a relative resistance of solid tumor cells to immunologic effector cells was shown in vitro. This resistance could be one reason for the clinical phenomenon of resistance of patients with colon carcinoma or other solid tumors to immunologic therapeutic approaches. In this study, dendritic cells (DCs) pulsed with CA 19-9 protein were tested for their immunostimulatory capacity of immunologic effector cells against cells derived from colon and pancreatic carcinoma. Dendritic cell cultures coexpressed CMRF-44 and CD1a, markers typical of DCs, in 31.5% ± 5.3% after 13 days of culture. Coculture of NK-like T lymphocytes with DCs led to a significant increase in cytotoxic activity, as measured using a lactate dehydrogenase release assay. Cytotoxic activity could be further increased using DCs pulsed with CA 19-9 protein. The effect of CA 19-9 on increasing the cytotoxic effect of NK-like T lymphocytes was dose dependent. Similarly, cocultivation of DCs with NK-like T cells derived from patients with metastatic pancreatic cancer and elevated CA 19-9 serum levels led to a significant increase in cytotoxic activity. In conclusion, DCs pulsed with CA 19-9 protein can increase the cytotoxic activity of immunologic effector cells against colon carcinoma and pancreatic cancer cells. Dendritic cells pulsed with CA 19-9 protein may have an important effect on immunotherapeutic protocols for patients with cancer.
ISSN:1524-9557
出版商:OVID
年代:2000
数据来源: OVID
|
|